Qiagen Starts Marketing Own Diagnostic Agents In Japan
This article was originally published in PharmAsia News
Executive SummaryGerman diagnostics maker Qiagen started marketing three diagnostic agents and two samplers in Japan. The three diagnostics agents use proprietary Hybrid Capture for human papillomavirus, chlamydia and gonococci DNA tests; the company also launched samplers for HPV and other sexually transmitted diseases. Previously, Qiagen products were marketed through Tokyo-based Mitsubishi Chemical Medicine. Qiagen Japanese subsidiary last year obtained the marketing approval and it is now co-promoting HPV products with Mitsubishi. Qiagen Japan has less than 20 sales representatives and the company plans to increase that number as its own marketing operations takes off. (Click here for more - Japanese language
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.